摘要
目的研究超声造影联合HER-2、TPS对乳腺癌新辅助化疗敏感性的预测价值。方法选取74例接受新辅助化疗的乳腺癌患者作为研究对象,根据新辅助化疗治疗效果分为敏感组(n=49)和不敏感组(n=25)。2组患者均接受超声造影检查,同时对比2组患者HER-2、组织多肽特异性抗原(TPS)水平,绘制ROC曲线分析超声造影联合HER-2、TPS对乳腺癌新辅助化疗敏感性的预测价值。结果与敏感组相比,不敏感组患者病灶始增时间和峰值时间显著更长(P<0.05);与敏感组相比,不敏感组患者血清HER-2和TPS水平显著更高(P<0.05)。应用受试者工作特征曲线评估乳腺癌新辅助化疗敏感性得出:超声造影预测乳腺癌新辅助化疗敏感性灵敏度89.8%和特异度为64.0%;HER-2预测乳腺癌新辅助化疗敏感性灵敏度为91.8%和特异度为80.0%;TPS预测乳腺癌新辅助化疗敏感性灵敏度91.9%和特异度为80.0%,三者联合预测乳腺癌新辅助化疗敏感性灵敏度为93.8%,特异度为92.0%,经分析得出,三者联合的预测灵敏度和特异度均高于各项单独检测(P<0.05)。结论超声造影联合HER-2、TPS对乳腺癌新辅助化疗敏感性的预测价值较高。
Objective To investigate the predictive value of contrast-enhanced ultrasound combined with human epidermal growth factor receptor(HER-2)and tissue polypeptide specific antigen(TPS)detection for sensitivity to neoadjuvant chemotherapy in breast cancer.Methods Seventy-four patients with breast cancer receiving neoadjuvant chemotherapy were enrolled,and divided into two groups according to the tumor response rate,sensitive group(n=49)and insensitive group(n=25).All patients received contrast-enhanced ultrasound examination,and serum levels of HER-2 and TPS were also detected,then receiver operating characteristic(ROC)curve was used to evaluate the predictive value of contrast-enhanced ultrasound combined with HER-2 and TPS detection for sensitivity to neoadjuvant chemotherapy in breast cancer.Results The arrival time(AT)and time to peak(TTP)were significantly longer in non-sensitive group than in sensitive group(P<0.05).Serum levels of HER-2 and TPS were also significantly higher in non-sensitive group than in sensitive group(P<0.05).In predicting the sensitivity to neoadjuvant chemotherapy in breast cancer,ROC curve found that the sensitivity and specificity were 89.8%and 64.0%for contrast-enhanced ultrasound examination,91.8%and 80.0%for HER-2 detection,91.9%and 80.0%for TPS detection,and 93.8%and 92.0%for the combined examination of the three,indicating that the combined examination of the three had the best predictive value(all P<0.05).Conclusion Contrast-enhanced ultrasound combined with HER-2 and TPS detection is of great predictive value for the sensitivity to neoadjuvant chemotherapy in breast cancer.
作者
吴豪杰
张伟
刘浏
程建中
WU Haojie;ZHANG Wei;LIU Liu(Zhumadian Central Hospital,Zhumadian,463000)
出处
《实用癌症杂志》
2022年第7期1211-1214,共4页
The Practical Journal of Cancer
基金
2018年度河南省医学科技攻关计划项目(编号:2018020735)。
关键词
超声造影
HER-2
TPS
乳腺癌
新辅助化疗
Contrast-enhanced ultrasound
HER-2
TPS
Breast cancer
Neoadjuvant chemotherapy
